ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with Glioblastoma multiforme (GBM) the most deadliest form of brain cancer using its patented Gliovac/ERC1671 vaccine.